Department of Radiation Oncology, Perrino Hospital, 72100, Brindisi, Italy.
School of Medicine and Surgery, University of Milan Bicocca, Milan, Italy.
Clin Genitourin Cancer. 2024 Aug;22(4):102102. doi: 10.1016/j.clgc.2024.102102. Epub 2024 Apr 24.
To retrospectively report long term outcomes following postoperative hypofractionated radiotherapy (RT) for prostate cancer, emphasizing treatment related toxicity.
Patients for whom adjuvant or salvage RT was indicated after prostatectomy were treated with a course of moderate hypofractionation consisting in the delivery of 62.5 Gy in 25 fractions (2.5 Gy per fraction) on the prostate bed in 5 consecutive weeks (EQD2 = 70 Gy) by means of 3D-CRT in most of them. Androgen deprivation therapy (ADT) was allowed at physician's discretion. Patients were evaluated for urinary and rectal complications according to the Common Terminology Criteria for Adverse Events v4 (CTCAE v.4). Overall survival (OS), biochemical recurrence free survival (bRFS), and metastasis-free survival (MFS) were estimated using the Kaplan-Meier method.
One hundred and ten patients with a median age of 67 years (range 51-78) were enrolled. The majority of them (82%) had adverse pathologic features only, while 31 (28%) had early biochemical relapse. Median PSA level before RT was 0.12 ng/mL (range 0-9 ng/mL). Median time from surgery was 4 months (range 1-136 months). Twenty-eight patients (25.4%) also received ADT. At a median follow up of 103 months (range 19-138 months), late Grade 3 and Grade 4 rectal toxicity were 0.9% (1 case of hematochezia) and 0.9% (1 case of fistula), respectively, while late Grade 3 GU side effects (urethral stenosis) occurred in 9 cases (8%). No late Grade 4 events were observed, respectively. Ten-year OS, b-RFS and MFS were 77.3% (95%CI: 82.1%-72.5%), 53.3% (95%CI: 59.9%-47.6%), and 76.7% (95%CI: 81.2%-72.2%), respectively.
Our study provides long term data that a shortened course of postoperative RT is as safe and effective as a long course of conventionally fractionated RT and would improve patients' convenience and significantly reduce RT department workloads.
回顾性报告前列腺癌术后接受低分割放疗(RT)的长期结果,强调与治疗相关的毒性。
对前列腺切除术后辅助或挽救性 RT 指征的患者,采用中分割方案治疗,即前列腺床 25 次分割(每次 2.5 Gy),共 5 周(EQD2 = 70 Gy),大多数患者采用 3D-CRT。允许医生选择雄激素剥夺治疗(ADT)。根据通用不良事件术语标准 4.0(CTCAE v.4)评估尿和直肠并发症。使用 Kaplan-Meier 法估计总生存(OS)、生化无复发生存(bRFS)和无转移生存(MFS)。
共纳入 110 例中位年龄 67 岁(51-78 岁)的患者。大多数患者(82%)仅存在不良病理特征,31 例(28%)出现早期生化复发。RT 前中位 PSA 水平为 0.12 ng/mL(0-9 ng/mL)。中位手术时间为 4 个月(1-136 个月)。28 例(25.4%)患者还接受 ADT。中位随访 103 个月(19-138 个月)时,晚期 3 级和 4 级直肠毒性分别为 0.9%(1 例便血)和 0.9%(1 例瘘管),9 例(8%)出现晚期 3 级 GU 副作用(尿道狭窄)。分别未观察到晚期 4 级事件。10 年 OS、b-RFS 和 MFS 分别为 77.3%(95%CI:82.1%-72.5%)、53.3%(95%CI:59.9%-47.6%)和 76.7%(95%CI:81.2%-72.2%)。
我们的研究提供了长期数据,表明缩短术后 RT 疗程与常规分割 RT 一样安全有效,可提高患者的便利性,并显著减少 RT 部门的工作量。